AZD0424_product_DataBase

Bioactivity	AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity[1]. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells[2].
Target	Src/Abl kinase inhibitor (SrcK-I), apoptosis
Invitro	AZD0424 (1-5 μM; 24-48 hours) is emerged to be the more effective of the three tested inhibitors (AZM559756, AZD0530 and AZD0424), inducing the highest levels of apoptosis with the lowest concentrations in lymphoma cells[2].AZD0424 (5 μM; 48 hours) leads to increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells, whereas the cell cycle progression of the nonsensitive cell lines Raji and Jurkat remains unaffected[2]. Apoptosis Analysis[2] Cell Line:
Name	AZD0424
CAS	692054-06-1
Formula	C25H29ClN6O5
Molar Mass	528.99
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Woodcock VK, et al. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Br J Cancer. 2018 Mar 20;118(6):770-776. [2]. Nowak D, et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007 Oct;18(9):981-95.

PeptideDB